Exelixis Collaboration Agreements
46 Contracts & Agreements
- Fifth Amendment dated August 24, 2023, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on November 1, 2023)
- Fourth Amendment dated October 11, 2022, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 7, 2023)
- Second Amendment dated May 7, 2019, to Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)
- Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)
- Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
- Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
- First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
- Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)
- Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on November 5, 2020)
- Second Amendment dated May 7, 2020, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Myers Squibb... (Filed With SEC on August 6, 2020)
- Amendment No. 3 dated November 22, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on February 25, 2020)
- Amendment No. 2 dated August 15, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Myers Squibb Company (Filed With SEC on October 30, 2019)
- Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on July 31, 2019)
- Amendment No. 1 dated March 8, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on May 1, 2019)
- Ono Territorial Supplemental Agreement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Ono Pharmaceutical Co., Ltd. and... (Filed With SEC on November 1, 2018)
- Supplement dated July 6, 2018 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Takeda... (Filed With SEC on November 1, 2018)
- First Amendment dated July 6, 2018 to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb... (Filed With SEC on November 1, 2018)
- First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on August 1, 2018)
- Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 26, 2018)
- Second Amendment dated September 14, 2017, to Collaboration and License Agreement by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on November 1, 2017)
- Third Amendment to the Collaboration Agreement (Filed With SEC on August 2, 2017)
- SUPPLEMENT TO THE CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on May 1, 2017)
- CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on May 1, 2017)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 1, 2017)
- First Amendment to the Collaboration Agreement (Filed With SEC on February 27, 2017)
- COLLABORATION AGREEMENT (Filed With SEC on February 27, 2017)
- FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 27, 2017)
- AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on August 3, 2016)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 4, 2016)
- COLLABORATION AGREEMENT (Filed With SEC on July 31, 2014)
- AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on August 4, 2011)
- AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on August 4, 2011)
- AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on August 4, 2011)
- COLLABORATION AGREEMENT (Filed With SEC on February 22, 2011)
- AMENDMENT NO. 3TO THE COLLABORATION AGREEMENT BETWEEN EXELIXIS, INC., AND BRISTOL-MYERS SQUIBBCOMPANY (Filed With SEC on February 22, 2011)
- AMENDMENT NO. 3TO THE COLLABORATION AGREEMENT BETWEEN EXELIXIS, INC., AND BRISTOL-MYERS SQUIBBCOMPANY (Filed With SEC on February 22, 2011)
- COLLABORATION AGREEMENT (Filed With SEC on July 30, 2009)
- COLLABORATION AGREEMENT (Filed With SEC on March 10, 2009)
- First Amendment to the Collaboration Agreement (Filed With SEC on May 6, 2008)
- AMENDMENT NO. 1 TOTHE COLLABORATION AGREEMENT BETWEEN (Filed With SEC on November 5, 2007)
